Interaction between the anticancer drug cisplatin and the copper chaperone Atox1 in human melanoma cells

Protein and Peptide Letters

Volumn 21, Issue 1, 2014, Pages 63-68

  Palm Espling, Maria E ^a   Lundin, Christina ^a   Björn, Erik ^a   Naredi, Peter ^b   Wittung Stafshede, Pernilla ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Anticancer; Atox1; Cisplatin; Copper chaperone; Immunoprecipitation; Resistance

Indexed keywords

ANTINEOPLASTIC AGENT; ATOX1 PROTEIN; CELL PROTEIN; CHAPERONE; CISPLATIN; COPPER; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CELL LYSATE; CYTOPLASM; EX VIVO STUDY; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MASS SPECTROMETRY; MELANOMA; PROTEIN INTERACTION; PROTEIN TRANSPORT;

ANTIBODIES; ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE, TUMOR; CISPLATIN; COPPER; HUMANS; IMMUNOPRECIPITATION; MAGNETITE NANOPARTICLES; MASS SPECTROMETRY; MELANOMA; METALLOCHAPERONES; PROTEIN BINDING;

EID: 84891468313     PISSN: 09298665     EISSN: None     Source Type: Journal    
DOI: 10.2174/09298665113209990036     Document Type: Article

References (23)

1. Rabik, C.A.; Dolan, M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev., 2007, 33, 9-23.
2. Katano, K.; Kondo, A.; Safaei, R.; Holzer, A.; Samimi, G.; Mishima, M.; Kuo, Y.-M.; Rochdi, M.; Howell, S.B. Acquisition of resistance to Cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res., 2002, 62, 6559-6565.
3. Howell, S.B.; Safaei, R.; Larson, C.A.; Sailor, M.J. Copper transporters and the cellular pharmacology of the platinumcontaining cancer drugs. Mol. Pharmacol., 2010, 77, 887-894.
4. Holzer, A.K.; Howell, S.B. The internalization and degradation of human copper transporter 1 following Cisplatin exposure. Cancer Res., 2006, 66, 10944-10952.
5. Liang, Z.D.; Long, Y.; Tsai, W.-B.; Fu, S.; Kurzrock, R.; GageaIurascu, M.; Zhang, F.; Chen, H.H.W.; Hennessy, B.T.; Mills, G.B.; Savaraj, N.; Kuo, M.T. Mechanistic basis for overcoming platinum resistance using copper chelating agents. Mol. Cancer Therap., 2012, 11, 2483-2494.
6. Samimi, G.; Safaei, R.; Katano, K.; Holzer, A.K.; Rochdi, M.; Tomioka, M.; Goodman, M.; Howell, S.B. Increased expression of the copper efflux transporter ATP7A mediates resistance to Cisplatin, Carboplatin, and Oxaliplatin in ovarian cancer cells. Clin. Cancer Res., 2004, 10, 4661-4669.
7. Katano, K.; Safaei, R.; Samimi, G.; Holzer, A.; Tomioka, M.; Goodman, M.; Howell, S. B. Confocal microscopic analysis of the interaction between Cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells. Clin. Cancer Res., 2004, 10, 4578-4588.
8. Komatsu, M.; Sumizawa, T.; Mutoh, M.; Chen, Z.-S.; Terada, K.; Furukawa, T.; Yang, X.-L.; Gao, H.; Miura, N.; Sugiyama, T.; Akiyama, S.-i. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with Cisplatin resistance. Cancer Res., 2000, 60, 1312-1316.
9. Anastassopoulou, I.; Banci, L.; Bertini, I.; Cantini, F.; Katsari, E.; Rosato, A. Solution structure of the apo and copper(I)-loaded human metallochaperone HAH1. Biochemistry, 2004, 43, 13046-13053.
10. Palm, M.E.; Weise, C.F.; Lundin, C.; Wingsle, G.; Nygren, Y.; Björn, E.; Naredi, P.; Wolf-Watz, M.; Wittung-Stafshede, P. Cisplatin binds human copper chaperone Atox1 and promotes unfolding in vitro. Proc. Natl. Acad. Sci. USA, 2011, 108, 6951-6956.
11. Beltramini, M.; Lerch, K. Primary structure and spectroscopic studies of neurospora copper metallothionein. Environ. Health Perspect., 1986, 65, 21-27.
12. Stillman, M.J.; Presta, A.; Gui, Z.; Jiang, D.T. Spectroscopic studies of copper, silver and gold-metallothioneins. Met. Based Drugs, 1994, 1, 375-94.
13. Presta, A.; Green, A.R.; Zelazowski, A.; Stillman, M.J. Copper binding to rabbit liver metallothionein. Formation of a continuum of copper(I)-thiolate stoichiometric species. Eur. J. Biochem., 1995, 227, 226-40.
14. Palm-Espling, M.E.; Andersson, C.D.; Björn, E.; Linusson, A.; Wittung-Stafshede, P. Determinants for simultaneous binding of copper and platinum to human chaperone Atox1: Hitchhiking not Hijacking. PLoS ONE, 2013, 8, e70473.
15. Boal, A. K.; Rosenzweig, A. C. Crystal structures of cisplatin bound to a human copper chaperone. J. Am. Chem. Soc., 2009, 131, 14196-7.
16. Dolgova, N.V.; Yu, C.H.; George, G.N.; Dmitriev, O.Y. Copper chaperone Atox1 interacts with the metal-binding domain of Wilson disease protein in Cisplatin detoxification. Biochem. J., 2013, 454(1), 147-56.
17. Arnesano, F.; Banci, L.; Bertini, I.; Felli, I.C.; Losacco, M.; Natile, G. Probing the interaction of Cisplatin with the human copper chaperone Atox1 by solution and in-cell NMR spectroscopy. J. Am. Chem. Soc., 2011, 133, 18361-18369.
18. Hemmingsson, O.; Zhang, Y.; Still, M.; Naredi, P. ASNA1, an ATPase targeting tail-anchored proteins, regulates melanoma cell growth and sensitivity to cisplatin and arsenite. Cancer Chemother. Pharmacol., 2009, 63, 491-499.
19. Tran, M.Q.T.; Nygren, Y.; Lundin, C.; Naredi, P.; Björn, E. Evaluation of cell lysis methods for platinum metallomic studies of human malignant cells. Analyt. Biochem., 2010, 396, 76-82.
20. Ha, Y.; Tsay, O.; Churchill, D. A tutorial and mini-review of the ICP-MS technique for determinations of transition metal ion and main group element concentration in the neurodegenerative and brain sciences. Monatsh Chem., 2011, 142, 385-398.
21. Björn, E.; Nygren, Y.; Thi Nhu Nguyen, T.T.; Ericson, C.; Nöjd, M.; Naredi, P. Determination of platinum in human subcellular microsamples by inductively coupled plasma mass spectrometry. Analyt. Biochem., 2007, 363, 135-142.
22. Dmitriev, O.Y. Mechanism of tumor resistance to cisplatin mediated by the copper transporter ATP7B. Biochem. Cell Biol., 2011, 89, 138-147.
23. Palm-Espling, M.E.; Wittung-Stafshede, P. Reaction of platinum anticancer drugs and drug derivatives with a copper transporting protein, Atox1. Biochem. Pharmacol., 2012, 83, 874-881.